L Härmark1, A C van Grootheest. 1. Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 's-Hertogenbosch, The Netherlands. l.harmark@lareb.nl
Abstract
BACKGROUND: Pharmacovigilance, defined by the World Health Organisation as 'the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem' plays a key role in ensuring that patients receive safe drugs. Our knowledge of a drug's adverse reactions can be increased by various means, including spontaneous reporting, intensive monitoring and database studies. New processes, both at a regulatory and a scientific level, are being developed with the aim of strengthening pharmacovigilance. On a regulatory level, these include conditional approval and risk management plans; on a scientific level, transparency and increased patient involvement are two important elements. OBJECTIVE: To review and discuss various aspects of pharmacovigilance, including new methodological developments.
BACKGROUND: Pharmacovigilance, defined by the World Health Organisation as 'the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem' plays a key role in ensuring that patients receive safe drugs. Our knowledge of a drug's adverse reactions can be increased by various means, including spontaneous reporting, intensive monitoring and database studies. New processes, both at a regulatory and a scientific level, are being developed with the aim of strengthening pharmacovigilance. On a regulatory level, these include conditional approval and risk management plans; on a scientific level, transparency and increased patient involvement are two important elements. OBJECTIVE: To review and discuss various aspects of pharmacovigilance, including new methodological developments.
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Johannes M Luteijn; Joan K Morris; Ester Garne; Joanne Given; Lolkje de Jong-van den Berg; Marie-Claude Addor; Marian Bakker; Ingeborg Barisic; Miriam Gatt; Kari Klungsoyr; Anna Latos-Bielenska; Nathalie Lelong; Vera Nelen; Amanda Neville; Mary O'Mahony; Anna Pierini; David Tucker; Hermien de Walle; Awi Wiesel; Maria Loane; Helen Dolk Journal: Br J Clin Pharmacol Date: 2016-08-04 Impact factor: 4.335
Authors: Harald E Heemstra; Thijs J Giezen; Aukje K Mantel-Teeuwisse; Remco L A de Vrueh; Hubert G M Leufkens Journal: Drug Saf Date: 2010-02-01 Impact factor: 5.606
Authors: Suehyun Lee; Jongsoo Han; Rae Woong Park; Grace Juyun Kim; John Hoon Rim; Jooyoung Cho; Kye Hwa Lee; Jisan Lee; Sujeong Kim; Ju Han Kim Journal: Drug Saf Date: 2019-05 Impact factor: 5.606